Calithera announces first patient treated in phase 1 cohort of INCB01158 trial
Calithera announced the first patient has been treated in the Phase 1 cohort of INCB01158 in combination with Keytrudaź (pembrolizumab). INCB01158 is a potent, selective, oral inhibitor of arginase being developed pursuant to a global collaboration and license agreement with Incyte Corporation. October 19, 2017